Wells Fargo & Company Celldex Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 22,736 shares of CLDX stock, worth $994,927. This represents 0.0% of its overall portfolio holdings.
Number of Shares
22,736
Previous 21,615
5.19%
Holding current value
$994,927
Previous $907,000
7.28%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CLDX
# of Institutions
195Shares Held
63.4MCall Options Held
206KPut Options Held
176K-
Wellington Management Group LLP Boston, MA8.08MShares$353 Million0.05% of portfolio
-
Black Rock Inc. New York, NY4.69MShares$205 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.74MShares$164 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ3.39MShares$148 Million9.76% of portfolio
-
Eventide Asset Management, LLC Boston, MA3.33MShares$146 Million2.17% of portfolio
About Celldex Therapeutics, Inc.
- Ticker CLDX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,772,400
- Market Cap $2.05B
- Description
- Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...